Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Patent
1995-02-08
1997-02-25
Feisee, Lila
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
435 697, 514 12, 514825, 530350, 5303873, 530866, 530868, A61K 39395, A61K 3800, C12P 2104, C07K 14715
Patent
active
056056907
ABSTRACT:
A method for treating TNF-dependent inflammatory diseases in a mammal by administering a TNF antagonist, such as soluble TNFR.
REFERENCES:
patent: 4675285 (1987-06-01), Clark et al.
patent: 4770995 (1988-09-01), Rubin et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5512544 (1996-04-01), Wallach et al.
Beutler of Tumor Necrosis Factors . . . , Raven Press, 1185 Ave of the Americas, NY, NY, 10036.
Steiner, Biotechnology 12: 1313, Dec. 1994.
"US News & World Report", p. 13, Aug. 1, 1994.
Immunophysiology pp, 234-235, 1990, Oppenheim.
Pavillo-New Eng J of Med., "Mech. of Disease, Pathogenetic Mech. of Septic Shock", pp. 1471-1477, 1993.
Hoogenboom et al, Molecular Immunology 28(9):1027-1037 1991, "Construction & Expression of Ab-TNF fusion proteins".
Harris, The New England Journal of Med., 322(18): 1277-1289 (1990) "Mechanisms of Disease: Rheumatoid Arthritis".
Brennan et al, The Lancet, Jul. 29, 1993, 244-247 "Inhib. Effect of TNF-.alpha. Ab on Synovial Cell IL-1 Production in Rh. Arthritis".
Smith et al, Science, 248: 1019-1023, 1990 "A Receptor for TNF defines an Unusual Family of Cellular & Viral Proteins".
Bloom, J. Clin. Invest., 91: 1265-1266 (1993) "The Power of Negative Thinking".
Pennica et al., "Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin," Nature 312: 724 (1984).
Gray et al., "Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity," Nature 312: 721 (1984).
Baglioni et al., "Binding of Human Tumor Necrosis Factor to High Affinity Receptors on HeLa and Lymphoblastoid Cells Sensitive to Growth Inhibition," J. Biol. Chem. 260:13395 (1985).
Aggarwall et al., "Characterization of receptors for human tumour necrosis factor and their regulation by .gamma.-interferon," Nature 318:665 (1985).
Yoshie et al., "Binding and Crosslinking of .sup.125 I-Labeled Recombinant Human Tumor Necrosis Factor to Cell Surface Receptors," J. Biochem. 100:531 (1986).
Israel et al., "Binding of Human TNF-.alpha. to High-Affinity Cell Surface Receptors: Effect of IFN," Immunology Letters 12:217 (1986).
Creasley et al., "A high molecular weight component of the human tumor necrosis factor receptor is associated with cytotoxicity," Proc. Natl. Acad. Sci. USA 84:3293 (1987).
Stauber et al., "Human Tumor Necrosis Factor-.alpha. Receptor," J. Biol. Chem. 263:19098 (1988).
Aggarwal and Eessalu, "Induction of Receptors for Tumor Necrosis Factor-.alpha. by Interferons Is Not a Mojor Mechanism for Their Synergistic Cytotoxic Response," J. Biol. Chem. 263:10000 (1987).
Tsujimoto et al., "Interferon-.gamma. Enhances Expression of Cellular Receptors for Tumor Necrosis Factor," J. Immun. 136:2441 (1987).
Holtmann and Wallach, "Down Regulation of the Receptors for Tumor Necrosis Factor by Interleukin 1 and 4.beta.-Phorbol-12-Myristate-13-Acetate," J. Immonol. 139:1161 (1987).
Shalaby et al., "Receptor Binding and Activation of Polymorphonuclear Neutrophils by Tumor Necrosis Factor-Alpha," J. Leukocyte Biol. 41:196 (1987).
Unglaub et al, "Downregulation of Tumor Necrosis Factor (TNF) Sensitivity Via Modulation of TNF Binding Capacity by Protein Kinase C Activators," J. Exp. Med. 166:1788 (1987).
Yonehara et al., "A Cell-Killing Monoclonal Antibody (ANTI-Fas) to a Cell Surface Antigen Co-Downregulated with the Receptor of Tumor Necrosis Factor," J. Exp. Med. 167:1511 (1988).
Peetre et al., "A tumor necrosis factor binding protein is present in human biological fluids," Eur. J. Haematol. 41:414 (1988).
Seckinger et al., "A Human Inhibitor of Tumor Necrosis Factor .alpha.," J. Exp. Med. 167:1511 (1988).
Seckinger et al., "Purification and Biologic Characterization of a Specific Tumor Necrosis Factor .alpha. Inhibitor," J. Biol. Chem. 264:11966 (1989).
Engelmann et al., "A Tumor Necrosis Factor-binding Protein Purified to Homogeneity from Human Urine Protects Cells from Tumor Necrosis Factor Toxicity," J. Biol. Chem. 264:11974 (1989).
Okayama and Berg, "High-Efficiency Cloning of Full-Length cDNA," Mol. Cell. Biol. 2:161 (1982).
Okayama and Berg, "A cDNA Cloning Vector That Permits Expression of cDNA Inserts in Mammalian Cells," Mol. Cell. Biol. 3:280 (1983).
Aruffo and Seed, "Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system," Proc. Natl. Acad. Sci. USA 84:8573 (1987).
Yamasaki et al., "Cloning and Expression of the Human Interleukin-6 (BSF-2/IFN.beta. 2) Receptor," Science 241:825 (1988).
Sims et al., "cDNA Expression Cloning of the IL-1 Receptor, a Member of the Immunoglobulin Superfamily," Science 241:585 (1988).
Tsujimoto et al., Arch. Biochem. and Biophys., "Characterization and Affinity Crosslinking of Receptors for Tumor Necrosis" 563-568 (1986).
Suggs et al., "Use of synthetic oligonucleotides as hybridization probes", PNAS 78:6613-6617 (1981).
Kull et al., "Cellular receptor for .sup.125 I-labelled tumor necrosis factor . . .", PNAS 82:5756-5760 (1985).
Smith et al., "A receptor for tumor necrosis factor defines and unusual family of cellular and viral proteins", Science 248:1019-1023 (1990).
Meller et al., "Complementary DNA cloning of a receptor for tumor necrosis factor and demonstration of a shed form of the receptor" Proc. Natl. Acad. Sci. U.S., 87:6151-6155 (1990).
Loetscher et al., "Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor" Cell 61:351-359 (1990).
Schall et al., "Molecular cloning and expression of a receptor for human tumor necrosis factor" Cell 61:361-370 (1990).
Engelmann et al., "Two tumor necrosis factor-binding proteins purified from human urine" J. Biol. Chem. 265:1531-1536.
Smith et al., "Blocking of HIV-1 Infectivity by a Soluble, Secreted Form of the CD4 Antigen", Science 238:1704-1707.
Jacobs Cindy A.
Smith Craig A.
Feisee Lila
Immunex Corporation
Lucas John
Malaska Stephen L.
LandOfFree
Methods of lowering active TNF-.alpha. levels in mammals using t does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of lowering active TNF-.alpha. levels in mammals using t, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of lowering active TNF-.alpha. levels in mammals using t will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1972650